跳至主要内容
临床试验/NCT06709144
NCT06709144进行中(未招募)3 期

Borderline of CME/D3 Dissection for Local Advanced Right-sided Colon Cancer(BLARCC): a Prospective, Multicenter Randomized Control Clinical Trial

Haixing Ju, MD1 个研究点 分布在 1 个国家目标入组 896 人开始时间: 2024年7月1日最近更新:
适应症

试验速览

阶段
3 期
状态
进行中(未招募)
发起方
入组人数
896
试验地点
1
主要终点
3 year DFS

研究概览

简要总结

The study was conducted on patients with advanced right-sided colon cancer, and the clinical pathological and prognostic data of the patients were compared between the two groups of patients who were randomly divided into those undergoing SMV and SMA left resection, with the aim of resolving the controversy over the left resection boundary of CME/D3 lymph node dissection through this study, and to clarify whether SMA left resection is superior to SMV left resection.

研究设计

研究类型
Interventional
分配方式
Randomized
干预模型
Single Group
主要目的
Treatment
盲法
None

入排标准

年龄范围
18 Years 至 78 Years(Adult, Older Adult)
性别
All
接受健康志愿者

入选标准

  • right side colon cancer(The primary lesion is located in the ileocecal region, ascending colon, hepatic flexure of colon, or proximal transverse colon)
  • T3-4 and/or N1-2M0
  • Colonoscopy and pathological biopsy confirmed colon adenocarcinoma

排除标准

  • Cannot undergo curative resection
  • Simultaneous multiple primary colorectal cancer or other diseases requiring segmental resection
  • Distant metastasis
  • Tumor invades surrounding organs, requiring joint organ resection
  • Emergency surgery is required for complications such as intestinal obstruction, perforation, and bleeding
  • Patients who have received neoadjuvant therapy before surgery
  • Pregnant or lactating women
  • Patients who are not suitable or unable to tolerate surgery

结局指标

主要结局

3 year DFS

时间窗: 3 years

3 year disease free survival

次要结局

  • 5 year OS(5 years)

研究者

发起方
Haixing Ju, MD
申办方类型
Other
责任方
Sponsor Investigator
主要研究者

Haixing Ju, MD

Director

Zhejiang Cancer Hospital

研究点 (1)

Loading locations...

相似试验